TITLE

Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

AUTHOR(S)
Kühne, Thomas; Imbach, Paul; Kühne, Thomas
PUB. DATE
July 2010
SOURCE
Annals of Hematology;Jul2010, Vol. 89, p67
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Immune thrombocytopenia (ITP) is characterised by a transient or persistent decrease in platelets accompanied by an increased risk of bleeding, which can have a significant negative impact on patients' health-related quality of life. The condition has long been associated with an increased rate of immune-mediated platelet destruction, and traditional treatments have targeted the reduction in platelet destruction; however, some interventional drugs are limited by transient efficacy and side effects. Recent advances in our understanding of ITP pathogenesis have highlighted the role of impaired platelet production, which has led to the advent of a new generation of thrombopoietin (TPO)-receptor agonist therapies, including eltrombopag and romiplostim. The oral, non-peptide TPO-receptor agonist eltrombopag has shown considerable promise in both preclinical and clinical trials. Eltrombopag has a unique mechanism of action and binds to a transmembrane region of the TPO receptor that is distant from the TPO binding site. As such, eltrombopag may confer synergistic effects with endogenous TPO rather than competing for binding. Eltrombopag also induces activation of the TPO receptor and downstream signalling in a distinct manner to TPO and does not have a significant impact on platelet function. Clinical evidence demonstrates that eltrombopag produces a rapid and sustainable increase in platelet counts that significantly reduces bleeding and is well tolerated in patients with ITP. Eltrombopag therefore represents an important addition to the therapeutic armamentarium for ITP.
ACCESSION #
52022216

 

Related Articles

  • Moving towards a new era in the management of chronic immune thrombocytopenia. Wadenvik, Hans; Olsson, Bob // Annals of Hematology;Jul2010, Vol. 89, p87 

    Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease in which a low concentration of plasma thrombopoietin (TPO) contributes to the thrombocytopenia. Functional thrombopoietin deficiency in response to thrombocytopenia is central to the pathophysiology of chronic ITP. Decreased...

  • Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Salama, A.; Rieke, M.; Kiesewetter, H.; Depka, M.; von Depka, M // Annals of Hematology;Jan2009, Vol. 88 Issue 1, p11 

    Patients with severe and refractory autoimmune thrombocytopenia (ITP) have significant morbidity and mortality rates. Currently, high-dose methylprednisolone and/or high-dose IVIgG are recommended for the emergency treatment of such patients with uncontrolled bleeding. However, some patients do...

  • Evaluating bleeding severity in immune thrombocytopenia (ITP). Neunert, Cindy E. // Annals of Hematology;Jul2010, Vol. 89, p47 

    Despite immune thrombocytopenia (ITP) being one of the most common conditions encountered by the pediatric hematologist, relatively few prospective investigations of ITP exist, and treatment approaches remain highly variable. The ideal prospective clinical trial would use a reduction in severe...

  • Thrombocytopenic Purpura. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p638 

    An encyclopedia entry for thrombocytopenic purpura is presented. It is a rare autoimmune disorder characterized by a shortage of platelets. This leads to bruising and spontaneous bleeding. Most of the cases are idiopathic while others are caused by drugs, infections or autoimmune disorders such...

  • Hidden maternal autoimmune thrombocytopenia complicated by fetal subdural hematoma-case report and review of the literature. Rios, Lívia; Araujo Júnior, Edward; Nardozza, Luciano; Haratz, Karina; Moron, Antonio; Martins, Marília // Child's Nervous System;Jul2012, Vol. 28 Issue 7, p1113 

    The article presents case study of having subdural hematoma related to fetal autoimmune thrombocytopenia. It has been informed that a 35-year-old primigravida was referred for routine scan at 34 gestational weeks (GW) and a full-term boy was delivered by cesarean section at 39 GW with a...

  • Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome. Choung, Bum-Su; Yoo, Wan-Hee // Rheumatology International;May2012, Vol. 32 Issue 5, p1353 

    Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by xerophthalmia, xerostomia and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders, including lymphoma are well-known extraglandular, hematological complications of SS. We...

  • The Ratio of Treg/Th17 Cells Correlates with the Disease Activity of Primary Immune Thrombocytopenia. Lili Ji; Yanxia Zhan; Fanli Hua; Feng Li; Shanhua Zou; Weiguang Wang; Dongli Song; Zhihui Min; Hao Chen; Yunfeng Cheng // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: Primary immune thrombocytopenia (ITP) is an autoimmune heterogeneous disorder that is characterized by decreased platelet count. Regulatory T (Treg) cells and T helper type 17 (Th17) cells are two subtypes of CD4+ T helper (Th) cells. They play opposite roles in immune tolerance and...

  • Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia. Tamary, Hannah; Roganovic, Jelena; Chitlur, Meera; Nugent, Diane; Nugent, Diane J // Annals of Hematology;Jul2010, Vol. 89, p5 

    The rarity of severe complications of this disease in children makes randomized clinical trials in immune thrombocytopenia (ITP) unfeasible. Therefore, the current management recommendations for ITP are largely dependent on clinical expertise and observations. As part of its discussions during...

  • Future research in ITP: an ICIS consensus. Zehnder, James L.; Semple, John W.; Imbach, Paul; Neufeld, Ellis J.; Buchanan, George R.; Cines, Douglas B.; ICIS Study Group on Future Research in ITP // Annals of Hematology;Jul2010, Vol. 89, p19 

    While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics